Investors’ outlook regarding the stock price performance over the year has been split, with some feeling optimistic and others feeling pessimistic, as it’s been a mixed bag. Year to date metric has recorded a loss of -58.40%.However, over the last six months, we can see a stronger performance of -55.37%. Over the last 30 days, the price of AIM has leaped by -30.92%. And in the last five days, it has fallen by -23.75%.
AIM ImmunoTech Inc experienced a somewhat shaky performance in the stock market. The company’s stock reached a 1-year high of $0.62 on 04/11/24, while the lowest price for the same period was registered at $0.21 on 11/19/24.
52-week price history of AIM Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. AIM ImmunoTech Inc’s current trading price is -70.48% away from its 52-week high, while its distance from the 52-week low is -13.35%. The stock’s price range during this period has varied between$0.21 and $0.62. The AIM ImmunoTech Inc’s shares, which operate in the Healthcare, saw a trading volume of around 4.26 million for the day, a figure considerably higher than their average daily volume of 0.35 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
AIM ImmunoTech Inc (AIM) has experienced a quarterly decline of -53.54% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 11.66M and boasts a workforce of 26 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 0.3045, with a change in price of -0.1897. Similarly, AIM ImmunoTech Inc recorded 348,306 in trading volume during the last 100 days, posting a change of -50.90%.
AIM’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for AIM stands at 1.17. Similarly, the long-term debt-to-equity ratio is also 0.20.
AIM Stock Stochastic Average
AIM ImmunoTech Inc’s raw stochastic average for the past 50 days is presently 11.80%, as of today. This marks a decrease from the raw stochastic average of the last 20 days, which was 18.02%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 13.38% and 22.56%, respectively.
